Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 13, 2026, the Board of Directors (the "Board") of 60 Degrees Pharmaceuticals, Inc. (the "Company") appointed Eric Francois to serve as a member of the Board, effective immediately.

Mr. Francois is a strategic financial executive with over 20 years of leadership experience in the healthcare and life sciences sectors. He currently serves as an Independent Director of CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) and as an independent strategic advisor to emerging life sciences companies. Mr. Francois previously served as Managing Director in Healthcare Investment Banking at Raymond James and Credit Suisse, where he led numerous equity, debt, and M&A transactions for small- and mid-cap biotechnology companies. Prior to his investment banking roles, he was Chief Financial Officer of SCYNEXIS, Inc. (Nasdaq: SCYX), where he oversaw finance, corporate development, investor relations, and operations, and raised over $300 million in capital to support the company's growth through FDA approval and commercial launch. He has also served as an independent director of Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), including roles on its Audit and Compensation Committees. Mr. Francois began his career in equity capital markets at Cowen & Company and Lazard Frères and holds M.A. and B.A. degrees in business and economics from the Sorbonne University in Paris.

There are no arrangements or understandings between Mr. Francois and any other persons pursuant to which he was appointed as a director. There are no family relationships between Mr. Francois and any director or executive officer of the Company, and Mr. Francois has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Mr. Francois will receive compensation for his service on the Board consistent with the Company's standard compensation arrangements for non-employee directors.